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Objective. To test the predictive ability of remission in terms of long-term disability in patients with recent-onset
inﬂammatory polyarthritis (IP).
Methods. Consecutive patients with early IP, recruited between 1990 and 1994 (ﬁrst cohort) and 2000 and 2004 (second
cohort), were included in this study. Remission was deﬁned as the absence of clinically detectable joint inﬂammation on
a 51–joint count. In additional analyses, less stringent deﬁnitions of remission were used based on the 40– and 28–joint
counts. Remission was assessed at 1, 2, and 3 years after inclusion. A 5-year Health Assessment Questionnaire score >1
(moderate disability) was chosen as the primary outcome measure.
Results. A total of 841 and 498 patients from the ﬁrst and second cohorts, respectively, completed 5 years of followup.
In the ﬁrst cohort, patients with at least 1 episode of remission had lower odds of 5-year disability (odds ratio [OR] 0.26,
95% conﬁdence interval [95% CI] 0.17–0.41). The number of times in remission correlated with the odds of disability, with
a mean decrease in the probability of disability of 64% for each additional time point in remission (OR 0.38, 95% CI
0.28–0.52). The time until ﬁrst remission was not associated with functional disability. Remission according to less
stringent criteria showed a weaker protection against future disability. Similar results were found in the second cohort.
Conclusion. Patients with IP achieving a state of sustained remission early are less likely to show long-term deterioration
of function compared with patients who do not achieve remission. The most persistent remission under the most stringent
deﬁnition of remission has the lowest probability of long-term disability.
INTRODUCTION
The aim of current treatment of inﬂammatory polyarthritis
(IP) is to achieve early and sustained control of joint in-
ﬂammation in order to provide relief of symptoms and to
prevent long-term detrimental outcomes such as joint
damage, functional disability, and increased mortality (1).
The relevance of aiming to suppress joint inﬂammation
primarily arises from pathophysiologic studies in patients
with chronic arthritis that clearly indicate the central role
of chronic inﬂammation in producing factors such as pro-
inﬂammatory cytokines that lead to structural deteriora-
tion of joints (2). Also, imaging studies in rheumatoid
arthritis (RA) suggest that the progression of joint damage
is related to the amount of synovial inﬂammation, even in
subclinical disease (3,4). Several clinical studies have
shown that early and/or aggressive therapeutic interven-
tions lead to complete control of disease activity, i.e.,
clinical remission, in an increasing proportion of patients
with early RA (5–10). Furthermore, these new treatment
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945strategies are able to modify the clinical course of the
disease in terms of clinical outcome, joint damage, and
functional disability (11–13).
Combining biologic and clinical data, aiming for remis-
sion seems to be the most effective strategy to prevent
long-term detrimental outcomes. Unfortunately, evidence
to support this simple statement from routine clinical
practice is lacking for some practical and conceptual rea-
sons. First, as different measures are in use for assessing
disease activity in RA, a consensus deﬁnition of clinical
remission in RA is currently unavailable (14). Second, it is
still unclear whether remission status might truly predict
relevant long-term outcomes such as future disease activ-
ity, structural damage, functional disability, and mortality.
These issues have been clearly outlined in a recent sys-
tematic review (15). Consistent data support that remis-
sion, regardless of the applied deﬁnition, is longitudinally
related to radiologic progression. Interestingly, there is
only limited evidence that remission might be longitudi-
nally associated with a better functional outcome. More
recently, Tanaka et al (16), studying a large cohort of
patients with established RA, identiﬁed an inverse corre-
lation between an index of cumulative remission over time
and the development of functional disability by the last
observation.
However, it is still unclear what the actual association is
between remission and long-term disability, what the ef-
fect is of a persistent status of remission on long-term
disability, and what the inﬂuence is of using different
deﬁnitions of remission on long-term disability.
The Norfolk Arthritis Register (NOAR) is a unique in-
ception cohort of patients with early IP who are followed
longitudinally using standardized protocols (17). Using
patients recruited by the NOAR, we therefore sought to
investigate the association between the time from symp-
tom onset until the ﬁrst remission, the status of sustained
remission, and the use of different deﬁnitions of remission
during the ﬁrst 3 years with functional disability at 5 years
after inclusion in the register.
SUBJECTS AND METHODS
Study design, setting, and participants. Since 1990, pa-
tients with early IP have been recruited to the NOAR, a
large primary care–based inception cohort in the east of
the UK. A detailed description of this register has been
reported elsewhere (17). Brieﬂy, consecutive cases of IP
are notiﬁed through general practitioners or attendance at
hospital rheumatology clinics within this catchment area.
The notiﬁcation criteria are adults ages 16 years at symp-
tom onset and swelling of at least 2 joints that has per-
sisted for at least 4 weeks. Individuals referred to the
register were subsequently assessed by a metrologist
within the next couple of weeks, in which steroid injec-
tions could have been given or disease-modifying anti-
rheumatic drugs (DMARDs) started. Those who were diag-
nosed by a hospital consultant with a condition other than
RA, IP, psoriatic arthritis, or viral arthritis, which ac-
counted for their joint symptoms, were excluded. For the
present study, we included only patients recruited be-
tween 1990 and 1994 (cohort 1) and between 2000 and
2004 (cohort 2) because in these two cohorts, patients were
assessed at baseline and at 1, 2, 3, and 5 years after inclu-
sion in the register. This study was conducted with the
approval of the Norfolk and Norwich University Hospital
Local Research Ethics Committee. All subjects gave writ-
ten consent.
Demographic and clinical assessments. At baseline, pa-
tients were assessed by a research nurse using a structured
interview and clinical examination. The baseline data in-
cluded demographics (age at onset of symptoms, sex, and
time from symptom onset to notiﬁcation to the NOAR),
comorbidities, and previous/current use of DMARDs. Start
and stop dates of DMARDs, including oral corticosteroids,
were also collected at each followup visit. At baseline and
followup, clinical assessments included the number of
swollen and tender joints (based on 51– and 28–joint
counts). Blood samples were taken to determine rheuma-
toid factor (RF) and C-reactive protein (CRP) levels (18,19).
The 28-joint Disease Activity Score (DAS28) using the CRP
level (20) was then calculated. The American College of
Rheumatology (ACR) 1987 criteria for RA (21) were ap-
plied cross-sectionally at baseline.
Remission. Remission was primarily deﬁned as no
swollen and no tender joints on examination of 51 joints
(deﬁnition 1). To make results more comparable with other
studies, remission was also deﬁned as no swollen and no
tender joints on examination of 40 of 51 assessed joints
(excluding neck, hips, and proximal interphalangeal
joints) (deﬁnition 2). In addition, less stringent deﬁnitions
of remission were applied: no swollen and no tender joints
based on the 28–joint count (deﬁnition 3), and 1 swollen
joint and 1 tender joint based on the 28–joint count
(deﬁnition 4). For each of these deﬁnitions of remission,
different remission states were deﬁned: 1) “remission ev-
er”: at least one assessment in remission within the ﬁrst 3
years, 2) “time to remission”: year of the ﬁrst assessment in
remission within the ﬁrst 3 years, 3) “remission score”:
times in remission within the ﬁrst 3 years, and 4) “re-
warded score”: remission score plus an extra point for
subsequent remissions and for remission at the last obser-
vation (third-year assessment) (22,23).
Patients showing a self-limiting IP, deﬁned as a persis-
tent absence of joint swelling and tenderness lasting from
the ﬁrst to the third year in the absence of DMARD treat-
ment, were classiﬁed as being in “natural remission” and
were not included in the analysis.
Functional disability. We included all patients who
completed the British version of the Health Assessment
Questionnaire (HAQ) at baseline and annually thereafter
until 5 years of followup (24). The main outcome of this
study was the 5-year HAQ score, dichotomized into ab-
sence versus presence of functional disability (HAQ score
1) (25–29).
Statistical analysis. Baseline differences between the
two cohorts were tested using Wilcoxon’s rank sum test for
946 Scire `e ta lcontinuous variables and the chi-square test for categorical
variables. The effect of remission on the development of
long-term disability was analyzed using logistic regression
models for the ﬁrst and second cohort separately, and odds
ratios (ORs) with 95% conﬁdence intervals (95% CIs) are
shown accordingly. Primary analysis investigated the as-
sociation between remission 1 and disability at 5 years,
including each of the following individual remission
states as independent variables in separate models: 1) “re-
mission ever,” 2) “time to remission,” 3) “remission
score,” and 4) “rewarded score.” The same analyses were
repeated adjusting for potential baseline confounders,
coded as follows: sex, RF (1:40), ACR criteria for RA, and
previous and/or concurrent treatment with DMARDs
and/or glucocorticoids as categorical variables, and symp-
tom duration, age in decades, and DAS28 and HAQ scores
as continuous variables. All confounders were entered and
retained in the model regardless of their statistical signif-
icance. Effect modiﬁcation was explored by ﬁtting interac-
tions in logistic models. The accuracy of the model was
analyzed using the area under the receiving operating
characteristic curve (AUC).
In secondary analysis, a second, third, and fourth set of
logistic regression models similar to the ﬁrst one were
generated, including remission variables (ever in remis-
sion, time to remission, remission score, and rewarded
score), according to deﬁnitions 2, 3, and 4, respectively.
A total of 1,098 patients from the ﬁrst cohort and 696
from the second cohort were eligible for the study. Of these
patients, 90 (8.1%) from the ﬁrst cohort and 57 (8.1%)
from the second cohort died during the followup period
under study; 161 (14.6%) and 121 (17.3%) subjects, re-
spectively, were lost to followup; and 3 (0.3%) and 15
(2.2%) patients, respectively, who fulﬁlled the criteria for
“natural remission” during the followup were excluded.
The study sample ﬁnally comprised 844 and 503 subjects
from the ﬁrst and second cohorts, respectively. HAQ score
was available for 841 and 498 subjects, respectively. Of the
841 and 498 evaluable subjects from the ﬁrst and second
cohorts with HAQ scores, respectively, 729 (86.7%) and
452 (90.8%), respectively, had complete data on joint
counts at every time point (1.3% missing at 1 year, 6.5%
missing at 2 years, and 8% missing at 3 years). Due to the
inclusion of several confounders, the number of subjects
with complete data available for the analyses fell to 583
(69.0%) and 326 (64.6%), respectively. To increase the
precision of our analyses, missing data on confounders
and joint counts were therefore imputed using switching
regression, an iterative multivariable regression technique
that retains an element of random variation in the esti-
mates (30). Using multiple imputation of remission vari-
ables and confounders, 841 and 498 subjects, respectively,
were ﬁnally available for all of the adjusted analyses. All
analyses were conducted using Stata, version 10 (Stata-
Corp).
RESULTS
Baseline characteristics of the study population are sum-
marized in Table 1. In general, the ﬁrst cohort comprised
patients with a shorter disease duration, higher disease
activity and disability, and lower prevalence of treatment
at the time of inclusion in the NOAR. There were both
Table 1. Baseline characteristics of cohort 1 (1990–1994) and cohort 2 (2000–2004)*
First cohort
(1990–1994)
Second cohort
(2000–2004)
N 841 498
Age at symptom onset, years 54.1 (42.7–65.1) 57.3 (47.8–68.3)†
Women, no. (%) 569 (67.7) 345 (69.3)
Symptom duration, months 5.52 (2.8–10.6) 8.15 (4.50–16.3)†
Current smoker, no. (%) 213 (25.3) 102 (20.5)
Satisﬁed 1987 ACR criteria for RA, no. (%) 398 (47.3) 236 (47.4)‡
Rheumatoid factor positive, no. (%)§ 208 (27.8) 153 (33.9)
Presence of nodules, no. (%) 56 (6.6) 34 (6.8)
Morning stiffness 30 (0–90) 30 (2–60)
Swollen joint count of 51 7 (2–13) 3 (1–7)†
Tender joint count of 51 8 (3–17) 4 (1–11)†
Swollen joint count of 28 5 (2–11) 2 (0–6)†
Tender joint count of 28 5 (2–11) 2 (0–7)†
CRP level, mg/liter¶ 5 (0–14.0) 8.6 (2.7–20.0)†
DAS28-CRP (3)¶ 3.94 (2.9–5.0) 3.53 (2.5–4.4)†
HAQ score 0.750 (0.2–1.4) 0.875 (0.4–1.6)†
Receiving DMARDs, no. (%) 146 (17.3) 229 (45.9)‡
Receiving steroids, no. (%) 52 (6.2) 137 (27.5)‡
* Values are the median (interquartile range) unless otherwise indicated. ACR  American College of Rheuma-
tology; RA  rheumatoid arthritis; CRP  C-reactive protein; DAS28-CRP  28-joint Disease Activity Score using
the CRP level; HAQ  Health Assessment Questionnaire; DMARDs  disease-modifying antirheumatic drugs.
† P  0.05 by Mann-Whitney U test.
‡ P  0.05 by chi-square test.
§ Rheumatoid factor measured on 748 and 457 subjects, respectively.
¶ CRP level measured on 688 and 420 subjects, respectively.
Remission in Early IP 947quantitative and qualitative differences in the therapeutic
management of the two cohorts. A total of 44.6% of pa-
tients in the ﬁrst cohort and 71.9% in the second cohort
were ever treated with DMARDs during followup. In the
ﬁrst cohort, the use of DMARDs was less persistent (me-
dian months receiving DMARDs 0 [interquartile range
(IQR) 0–47 months] versus 51 [IQR 0–60 months]). Fur-
thermore, DMARD treatment differed qualitatively be-
tween the two cohorts, with a lower use of methotrexate
ever in the ﬁrst cohort (20.3% versus 55.2%). These results
reﬂect the changing management of RA and IP during the
last two decades.
The prevalence of remission at each anniversary during
the ﬁrst 3 years of followup is shown in Table 2. There was
an increased prevalence of remission in the second cohort
compared to the ﬁrst cohort, regardless of the applied
deﬁnition of remission. The same trend was observed for
the cumulative prevalence of remission (remission ever)
and remission or rewarded scores. As expected, less strin-
gent deﬁnitions led to an increasing occurrence of remis-
sion in both cohorts. As a result of this, the occurrence of
remission ever ranged from 22.4% to 33.9% for the most
stringent criterion (deﬁnition 1) to 46.5% to 57.7% for the
most permissive one (deﬁnition 4) in the ﬁrst and second
cohorts, respectively. After 5 years of followup, 376
(44.7%) and 263 (52.8%) of subjects from the ﬁrst and
second cohorts, respectively, experienced at least moder-
ate disability (HAQ score 1).
Primary analysis in the ﬁrst cohort. In the ﬁrst cohort,
subjects who had experienced at least one period of remis-
sion according to deﬁnition 1 within the ﬁrst 3 years of
followup showed a 75% relative reduction in the odds of
being moderately disabled after 5 years (OR 0.25, 95% CI
0.17–0.37). This reduction was still 70% after adjusting
for baseline confounders (OR 0.33, 95% CI 0.20–0.54) and
optimizing information using multiple imputations of
missing data (adjusted OR 0.26, 95% CI 0.17–0.41) (Table
3). The same trend was seen for the imputed/adjusted data
and therefore, these ORs are shown for all analyses. No
signiﬁcant interactions were found between remission
variables and possible baseline confounders.
The timing of the ﬁrst achievement of remission within
the ﬁrst 3 years was not relevant in terms of future disabil-
ity. Although the achievement of the ﬁrst remission was
signiﬁcantly associated with a lower risk of disability at
each time point within the ﬁrst 3 years, no systematic
decrease in OR was found across the increasing time to the
ﬁrst remission.
Analyzing the subgroup of patients receiving treatment
with DMARDs during the followup, the achievement of
remission at the ﬁrst assessment was associated with the
lowest OR of disability (time to ﬁrst remission 1 year:
adjusted OR 0.14, 95% CI 0.04–0.44; 2 years: adjusted OR
0.25, 95% CI 0.10–0.65; and 3 years: adjusted OR 0.22,
95% CI 0.09–0.55). Conversely, in patients untreated with
DMARDs, the achievement of remission at the ﬁrst assess-
ment was associated with the higher OR of disability (time
to ﬁrst remission 1 year: adjusted OR 0.57, 95% CI 0.25–
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948 Scire `e ta l1.30; 2 years: adjusted OR 0.18, 95% CI 0.06–0.58; and 3
years: adjusted OR 0.40, 95% CI 0.13–1.13).
The number of assessments in remission (remission
score) was proportional to the odds of moderate disability,
with a mean decrease in the probability of moderate dis-
ability of 64% for each time point in remission (adjusted
OR 0.38, 95% CI 0.28–0.52). The effect of remission score
was linearly associated with the outcome, leading to a
proportional reduction of the odds of disability for each
increasing point of remission score (1-point score: ad-
justed OR 0.36, 95% CI 0.23–0.58; 2-point score: adjusted
OR 0.14, 95% CI 0.05–0.36; and 3-point score: adjusted OR
0.07, 95% CI 0.00–0.66). Similar results were obtained for
the rewarded score. Using the rewarded score instead of
the simple remission score did not signiﬁcantly modify the
accuracy of the regression model (AUC 0.824, 95% CI
0.803–0.846 versus AUC 0.824, 95% CI 0.802–0.846).
Primary analysis in the second cohort. The analysis of
the second cohort conﬁrmed the longitudinal effect of a
remission status achieved within the ﬁrst 3 years on 5-year
moderate disability (Table 3). In the unadjusted analyses,
the effect of remission on 5-year HAQ score was slightly
higher in the second cohort compared to the ﬁrst cohort
(OR 0.15, 95% CI 0.10–0.24 versus OR 0.25, 95% CI 0.17–
0.37), but this difference disappeared after adjusting for
confounders and using multiple-imputed data sets (ad-
justed OR 0.26, 95% CI 0.17–0.41 versus OR 0.27, 95% CI
0.16–0.44). The accuracy of the models ﬁtted on the sec-
ond set of data was as good as that observed in the ﬁrst one
(AUC 0.818, 95% CI 0.795–0.840 for the adjusted model,
including remission score), conﬁrming that the observed
relationship between remission and future disability is
independent of the cohort and the treatment received.
Secondary analysis. To make results more comparable
with our studies, we also tested an alternative deﬁnition of
remission 1 as no swollen and no tender joints on exami-
nation of 40 of 51 joints assessed. Both prevalence (agree-
ment 98.2%) and effect measures of remission according to
these two deﬁnitions were highly consistent in both co-
horts (Table 3).
In order to verify the relevance of a stricter deﬁnition of
remission on future disability, we tested and compared the
effect of 2 other deﬁnitions that were progressively more
permissive in terms of residual joint involvement (Table
3). Clinical remission, even according to the more permis-
sive criteria, was associated with a better functional out-
come. Slight differences between the two cohorts were
observed. A trend to a decreasing protective effect for less
stringent remission criteria was more evident in the sec-
ond cohort than in the ﬁrst cohort.
Since less stringent criteria also included subjects ful-
ﬁlling more stringent criteria, we used contrasts to sepa-
rate the single effect of each deﬁnition (Table 4). Overall,
subjects in remission according to the most stringent cri-
terion (deﬁnition 1) showed the lowest probability of
5-year disability.
In the ﬁrst cohort, the subgroup of subjects in remission
according to deﬁnition 3 but not deﬁnition 1 showed a
beneﬁt on future disability, while subjects in remission
only according to deﬁnition 4 did not. In the second co-
Table 3. Effect of remission according to different deﬁnitions of remission on 5-year moderate disability (HAQ score >1)*
Cohort
Remission 1,
adjusted OR (95% CI)†
Remission 2,
adjusted OR (95% CI)‡
Remission 3,
adjusted OR (95% CI)§
Remission 4,
adjusted OR (95% CI)¶
Ever in remission
1990–1994 0.26 (0.17–0.41) 0.31 (0.20–0.46) 0.23 (0.15–0.34) 0.31 (0.21–0.44)
2000–2004 0.27 (0.16–0.44) 0.31 (0.19–0.51) 0.39 (0.24–0.63) 0.51 (0.32–0.82)
Remission score
1990–1994 0.38 (0.28–0.52) 0.44 (0.33–0.59) 0.40 (0.30–0.52) 0.47 (0.37–0.59)
2000–2004 0.43 (0.31–0.58) 0.45 (0.34–0.61) 0.51 (0.39–0.66) 0.55 (0.44–0.70)
Time to ﬁrst remission
1 year
1990–1994 0.28 (0.15–0.53) 0.39 (0.22–0.69) 0.27 (0.16–0.47) 0.37 (0.24–0.57)
2000–2004 0.29 (0.15–0.58) 0.31 (0.16–0.60) 0.35 (0.19–0.65) 0.45 (0.27–0.77)
2 years
1990–1994 0.22 (0.11–0.44) 0.20 (0.10–0.40) 0.18 (0.09–0.34) 0.19 (0.10–0.36)
2000–2004 0.24 (0.11–0.53) 0.25 (0.12–0.53) 0.33 (0.16–0.66) 0.49 (0.23–1.02)
3 years
1990–1994 0.30 (0.15–0.59) 0.33 (0.18–0.64) 0.24 (0.16–0.47) 0.30 (0.15–0.59)
2000–2004 0.26 (0.10–0.68) 0.45 (0.18–1.11) 0.63 (0.28–1.38) 0.85 (0.35–2.06)
Rewarded score
1990–1994 0.54 (0.44–0.67) 0.60 (0.49–0.72) 0.56 (0.47–0.67) 0.62 (0.53–0.71)
2000–2004 0.57 (0.47–0.71) 0.60 (0.50–0.73) 0.65 (0.55–0.77) 0.69 (0.59–0.79)
* All analyses adjusted for age, sex, disease duration, rheumatoid factor, disease-modifying antirheumatic drug use at baseline, steroid use at baseline,
baseline 28-joint Disease Activity Score, baseline HAQ score, and baseline comorbidities. Based on multiple imputation of missing data. First cohort:
841 subjects, second cohort: 498 subjects. HAQ  Health Assessment Questionnaire; OR  odds ratio; 95% CI  95% conﬁdence interval.
† Remission 1: 51–swollen joint count  51–tender joint count  0.
‡ Remission 2: 40–swollen joint count  40–tender joint count  0.
§ Remission 3: 28–swollen joint count  28–tender joint count  0.
¶ Remission 4: 28–swollen joint count 1 and 28–tender joint count 1.
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only in remission 4 gave a signiﬁcant effect on 5-year
disability. Analyzing both cohorts together, a signiﬁcant
trend toward the higher protective effect for the more
stringent criterion was found (score test for trend of odds P
 0.0001).
DISCUSSION
This study sought to determine the predictive value of a
pragmatic deﬁnition of remission on the development of
moderate disability by 5 years in a primary care–based
inception cohort of patients with IP. To our knowledge,
this is the largest study investigating the relationship be-
tween clinical remission and long-term functional out-
come in IP. The particular setting of the NOAR allowed us
to measure the effect of remission taking into account
several potential confounders, providing more precise and
less unbiased measures of effect. Due to the sequential
recruitment of patients we were also able to test and com-
pare such measures of effect in two separate cohorts, in-
creasing the generalizability of the results.
We found that the achievement of a status of remission
within the ﬁrst 3 years of followup was associated with a
fall of approximately 70% in the odds of moderate disabil-
ity after 5 years. This result is in keeping with previous
ﬁndings that describe a signiﬁcant difference of long-term
disability measures comparing patients who went into re-
mission with those who did not (31–33). In our analysis,
we also adjusted for baseline confounders, including the
HAQ and disease activity, which affect both the probabil-
ity of entering into a remission status and of being disabled
over time. Adjusted analyses better deﬁne the relationship
between remission and disability, limiting their intrinsic
association in patients with mild and nonprogressive dis-
ease.
Among subjects in clinical remission within the ﬁrst 3
years, there were subjects who fulﬁlled the criteria of
remission only once and subjects who were in remission
on 2 or 3 annual followup visits. The number of times
spent in remission showed a proportional effect on long-
term disability, with a relative decrease of the odds of 60%
for each assessment in remission within the ﬁrst 3 years.
As a result of this, the estimated risk of moderate disability
for subjects in remission at 3 followup visits was more
than 5 times lower than that of subjects who were in
remission only once. Previous studies have already iden-
tiﬁed an association between a persistent status of remis-
sion and a better radiographic outcome in patients with
RA (29,34). Our results support the clinical relevance of
aiming to achieve a persistent status of clinical remission.
Using a rewarded score, which gives more weight to
consecutive assessments and last assessment in remission,
we tried to identify the effect of persistent remission (23).
The lack of any advantage over remission score might be
due to the small number and frequency of assessments
included in our analysis rather than a true absence of
difference.
In this study, we included two cohorts of patients re-
cruited 10 years apart. We found a number of baseline and
longitudinal differences. The second cohort comprised pa-
tients with a longer mean symptom duration, higher dis-
ease activity, higher baseline disability, and higher preva-
lence of patients already receiving treatment at the time of
registration in the NOAR. On the other hand, due to the
higher disease activity and severity at baseline, a larger
proportion of patients from the second cohort developed at
least moderate disability after 5 years. Probably due to a
more intensive treatment strategy (more persistent and
aggressive DMARD therapy), a higher proportion of pa-
tients from the second cohort achieved a status of clinical
remission. Despite these differences, the effect of remis-
sion was highly consistent in both cohorts.
Interestingly, the time to ﬁrst remission within the ﬁrst 3
years did not affect the risk of 5-year disability. This is in
contrast to other published studies that suggest that early
intervention is associated with a lower risk of progression
of joint damage in RA and disability, probably due to the
earlier suppression of disease activity (11,33,35). One pos-
sible explanation for our results could be the width of the
window of opportunity for the prevention of disability.
Since a similar protective effect was evident for remission
achieved at each time point between 1 and 3 years, we can
speculate that the opportunity for preventing long-term
disability is wider than 3 years. A second explanation
could be the loss of the sustained effect on long-term HAQ
score of an earlier clinical response, as previously reported
(36), or the different effect on disease activity and disease
severity components of the HAQ. A further explanation
relies on the applied study design. In our observational
Table 4. Speciﬁc effect of remission according to different deﬁnitions of remission on 5-year moderate disability
(HAQ score >1)*
Ever in remission according
to deﬁnition
First cohort (1990–1994),
adjusted OR (95% CI)
Second cohort (2000–2004),
adjusted OR (95% CI)
All subjects,
adjusted OR (95% CI)
No remission deﬁnitions 1 1 1
Remission 4 deﬁnition 0.84 (0.46–1.55) 1.17 (0.55–2.49) 0.95 (0.59–1.51)
Remission 3 and 4 deﬁnitions 0.22 (0.10–0.47) 1.16 (0.52–2.56) 0.46 (0.28–0.77)
Remission 1, 3, and 4 deﬁnitions 0.23 (0.15–0.35) 0.28 (0.16–0.48) 0.24 (0.17–0.34)
* Adjusted for age, sex, disease duration, rheumatoid factor, disease-modifying antirheumatic drug use at baseline, steroid use at baseline, baseline
28-joint Disease Activity Score, baseline HAQ score, and baseline comorbidities. Based on imputed missing data. First cohort: 841 subjects, second
cohort: 498 subjects. HAQ  Health Assessment Questionnaire; OR  odds ratio; 95% CI  95% conﬁdence interval; remission 4  28–swollen joint
count 1 and 28–tender joint count 1; remission 3  28–swollen joint count  28–tender joint count  0; remission 1  51–swollen joint count 
51–tender joint count  0.
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classiﬁcation criteria, disease activity and therapeutic de-
cision are strictly interdependent, so that more severe
disease is treated more intensively and less severe disease
is likely to be untreated. Moreover, remission in treated
patients is more likely to be more sustained between an-
nual clinical assessments, while in untreated patients it is
more likely to be a random ﬂuctuation around a status of
low disease activity. As a matter of fact, stratifying our
analyses by DMARD treatment over the ﬁrst 5 years, earlier
remission showed a trend of association with better func-
tional outcome in the subset of patients treated during the
followup.
We also explored the impact of deﬁnitions of remission
progressively more permissive in terms of residual joint
inﬂammation. Regardless of the applied deﬁnition, we
were able to detect a signiﬁcant protective effect of remis-
sion on the risk of moderate disability. Investigating the
speciﬁc effect of each deﬁnition of remission, we found
that the greatest effect was due to the fulﬁllment of the
most stringent deﬁnition. The additional protective effect
of remission based on less stringent criteria was not con-
sistent across the two cohorts or even no longer signiﬁcant.
This result is in keeping with the current belief that more
stringent criteria for remission (e.g., Simpliﬁed Disease
Activity Index, Clinical Disease Activity Index) could
identify a more robust status of complete disease control
compared with more permissive criteria (e.g., DAS28)
(14,37). This explorative analysis aimed to identify a rela-
tionship between “stringency” and long-term relevant out-
comes, rather than to provide a clinically applicable cutoff
for predicting future disability.
This study has some limitations. Due to the study de-
sign, we were not able to apply any of the current deﬁni-
tions of remission (neither dimensional criteria based on
speciﬁed cutoffs of continuous disease activity scores nor
categorical criteria based on fulﬁllment of prespeciﬁed
items) (14,37). Our deﬁnitions, only based on swollen and
tender joint counts, clearly lack content validity, since
they exclude acute-phase reactants and the patient’s or
assessor’s reported measures. Nevertheless, the lack of
complete content validity does not affect the predictive
validity of our deﬁnitions of remission.
The number of patients lost to followup was acceptable
for a longitudinal study (38). Subjects lost to followup but
still alive after 5 years were signiﬁcantly younger than
those who were lost to followup, but showed similar base-
line disease activity and functional disability. Conversely,
subjects who died during the followup were older and
showed higher disease activity and disability than com-
pleters. These differences introduce a selection bias that
should be taken into account when interpreting our re-
sults.
In summary, this study demonstrates that achieving sus-
tained remission early in the disease course of IP is asso-
ciated with longitudinally better functional outcome. This
result strengthens the use of remission as a relevant dis-
ease outcome to target in clinical practice. More ambitious
targets, such as sustained remission and complete control
of joint inﬂammation, will be an even better outcome to
aim for in patients with IP in order to prevent future
disability. These results, tested and conﬁrmed in two sep-
arate sets of data, are likely to be generalizable to the entire
population of IP.
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